Charmacy Pharmaceutical Co., Ltd.
Simbols: 2289.HK
HKSE
10.6
HKDTirgus cena šodien
26.6977
P/E koeficients
-2.4737
PEG koeficients
1.14B
MRK Cap
- 0.07%
DIV ienesīgums
Charmacy Pharmaceutical Co., Ltd. (2289-HK) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2048.73 | 634.2 | 503.8 | 641.8 | |||||||||||
balance-sheet.row.short-term-investments | 33.27 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.net-receivables | 3455.49 | 965.4 | 865.3 | 731.3 | |||||||||||
balance-sheet.row.inventory | 2642.09 | 775.8 | 586.9 | 509.2 | |||||||||||
balance-sheet.row.other-current-assets | 1683.13 | 436.6 | 506.4 | 356 | |||||||||||
balance-sheet.row.total-current-assets | 9829.44 | 2812 | 2462.4 | 2238.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 1267.58 | 328.5 | 294.1 | 348.4 | |||||||||||
balance-sheet.row.goodwill | 24.1 | 6 | 6 | 6 | |||||||||||
balance-sheet.row.intangible-assets | 376.24 | 76.7 | 80.9 | 143 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 400.34 | 82.7 | 86.9 | 149.1 | |||||||||||
balance-sheet.row.long-term-investments | 1234.74 | 0 | 374.7 | 489.3 | |||||||||||
balance-sheet.row.tax-assets | 29.25 | 7.4 | 6.2 | 8.2 | |||||||||||
balance-sheet.row.other-non-current-assets | -1239.64 | 17 | -381 | -497.5 | |||||||||||
balance-sheet.row.total-non-current-assets | 1692.27 | 435.7 | 381 | 497.5 | |||||||||||
balance-sheet.row.other-assets | 71.28 | 0 | 22.6 | 27.4 | |||||||||||
balance-sheet.row.total-assets | 11593 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.account-payables | 3709.65 | 659.1 | 876.8 | 809.8 | |||||||||||
balance-sheet.row.short-term-debt | 5654.1 | 1531.1 | 1390 | 1512.6 | |||||||||||
balance-sheet.row.tax-payables | 296.21 | 56 | 94.2 | 44.6 | |||||||||||
balance-sheet.row.long-term-debt-total | 131.02 | 30.4 | 15.8 | 86.9 | |||||||||||
Deferred Revenue Non Current | -1.37 | -0.6 | 0 | 0.3 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.52 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 3492.36 | 2.5 | 1378.8 | 1349.2 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 132.52 | 31 | 15.8 | 86.9 | |||||||||||
balance-sheet.row.other-liabilities | 11.38 | 0 | 0 | 13.2 | |||||||||||
balance-sheet.row.capital-lease-obligations | 84.83 | 37 | 15.8 | 15.5 | |||||||||||
balance-sheet.row.total-liab | 9303.15 | 2649.8 | 2271.4 | 2259 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 432 | 108 | 108 | 108 | |||||||||||
balance-sheet.row.retained-earnings | 712.22 | 181.2 | 207.5 | 117.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 280.97 | 279 | 1 | 1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 864.66 | 29.7 | 278 | 278 | |||||||||||
balance-sheet.row.total-stockholders-equity | 2289.85 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 11593 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 2289.85 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 11593 | - | - | - | |||||||||||
Total Investments | 33.27 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.total-debt | 5796.4 | 1561.5 | 1405.8 | 1611.9 | |||||||||||
balance-sheet.row.net-debt | 3780.94 | 927.3 | 913.1 | 981.8 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 141.73 | 90.4 | 23.2 | 40.6 | ||||||||||
cash-flows.row.depreciation-and-amortization | 41.75 | 28.8 | 32 | 24.6 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | -404.55 | -300.2 | 20.9 | -227.9 | ||||||||||
cash-flows.row.account-receivables | -187.1 | -222.5 | -54.8 | -158 | ||||||||||
cash-flows.row.inventory | -217.45 | -77.7 | 75.8 | -69.8 | ||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-non-cash-items | 36.34 | 225 | -95.7 | 293.8 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -184.73 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -38.77 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | -2.9 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 160.41 | 80.4 | 0.6 | 0.1 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 121.65 | 71.8 | -24.4 | -54.8 | ||||||||||
cash-flows.row.debt-repayment | 0 | -1074.5 | -824.1 | -888.6 | ||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | -40.42 | -28.4 | -52.5 | -56.5 | ||||||||||
cash-flows.row.other-financing-activites | 52.15 | 911.7 | 951 | 942.5 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 11.73 | -191.2 | 74.4 | -2.7 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.05 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -51.31 | -75.4 | 30.5 | 73.6 | ||||||||||
cash-flows.row.cash-at-end-of-period | 332.42 | 68.9 | 144.2 | 113.8 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 383.73 | 144.2 | 113.8 | 40.1 | ||||||||||
cash-flows.row.operating-cash-flow | -184.73 | 44.1 | -19.5 | 131.1 | ||||||||||
cash-flows.row.capital-expenditure | -38.77 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.free-cash-flow | -223.5 | 35.5 | -44.6 | 79.1 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 8578.91 | 4403.6 | 4175.3 | 3793.6 | |||||||||||
income-statement-row.row.cost-of-revenue | 8017.56 | 4110.9 | 3906.7 | 3559.5 | |||||||||||
income-statement-row.row.gross-profit | 561.35 | 292.7 | 268.6 | 234.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 97.18 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 235.39 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.operating-expenses | 304.92 | 178 | 116.1 | 163.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 8322.48 | 4288.9 | 4022.8 | 3722.9 | |||||||||||
income-statement-row.row.interest-income | 66.96 | 4.3 | 30.5 | 37.7 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 235.39 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -12.61 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.total-operating-expenses | -12.61 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 53.79 | 26.5 | 25.7 | 29.1 | |||||||||||
income-statement-row.row.ebitda-caps | 255.88 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 202.09 | 66.2 | 93.5 | 74.4 | |||||||||||
income-statement-row.row.income-before-tax | 189.47 | 67.4 | 122.1 | 33 | |||||||||||
income-statement-row.row.income-tax-expense | 47.75 | 16.1 | 31.7 | 9.8 | |||||||||||
income-statement-row.row.net-income | 141.73 | 51.3 | 90.5 | 23.2 |
Biežāk uzdotie jautājumi
Kas ir Charmacy Pharmaceutical Co., Ltd. (2289.HK) kopējie aktīvi?
Charmacy Pharmaceutical Co., Ltd. (2289.HK) kopējie aktīvi ir 3247655876.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 4403633477.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.066.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -2.398.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.012.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.025.
Kāda ir Charmacy Pharmaceutical Co., Ltd. (2289.HK) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 51344725.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 1561459369.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 178011533.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 634197229.000.